171 related articles for article (PubMed ID: 38615022)
1. STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells.
Wang L; Liang Z; Guo Y; Habimana JD; Ren Y; Amissah OB; Mukama O; Peng S; Ding X; Lv L; Li J; Chen M; Liu Z; Huang R; Zhang Y; Li Y; Li Z; Sun Y
Cell Death Dis; 2024 Apr; 15(4):265. PubMed ID: 38615022
[TBL] [Abstract][Full Text] [Related]
2. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
[TBL] [Abstract][Full Text] [Related]
3. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract][Full Text] [Related]
4. Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4
Luo J; Pang S; Hui Z; Zhao H; Xu S; Yu W; Yang L; Sun Q; Hao X; Wei F; Wang J; Ren X
Theranostics; 2023; 13(14):4836-4857. PubMed ID: 37771774
[No Abstract] [Full Text] [Related]
5. Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression.
Wargo JA; Robbins PF; Li Y; Zhao Y; El-Gamil M; Caragacianu D; Zheng Z; Hong JA; Downey S; Schrump DS; Rosenberg SA; Morgan RA
Cancer Immunol Immunother; 2009 Mar; 58(3):383-94. PubMed ID: 18677478
[TBL] [Abstract][Full Text] [Related]
6. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
7. STING agonist diABZI induces PANoptosis and DNA mediated acute respiratory distress syndrome (ARDS).
Messaoud-Nacer Y; Culerier E; Rose S; Maillet I; Rouxel N; Briault S; Ryffel B; Quesniaux VFJ; Togbe D
Cell Death Dis; 2022 Mar; 13(3):269. PubMed ID: 35338116
[TBL] [Abstract][Full Text] [Related]
8. Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1
Shenderov E; Kandasamy M; Gileadi U; Chen J; Shepherd D; Gibbs J; Prota G; Silk JD; Yewdell JW; Cerundolo V
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088742
[TBL] [Abstract][Full Text] [Related]
9. NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.
Sommermeyer D; Conrad H; Krönig H; Gelfort H; Bernhard H; Uckert W
Int J Cancer; 2013 Mar; 132(6):1360-7. PubMed ID: 22907642
[TBL] [Abstract][Full Text] [Related]
10. NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
Ishihara M; Kitano S; Kageyama S; Miyahara Y; Yamamoto N; Kato H; Mishima H; Hattori H; Funakoshi T; Kojima T; Sasada T; Sato E; Okamoto S; Tomura D; Nukaya I; Chono H; Mineno J; Kairi MF; Diem Hoang Nguyen P; Simoni Y; Nardin A; Newell E; Fehlings M; Ikeda H; Watanabe T; Shiku H
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35768164
[TBL] [Abstract][Full Text] [Related]
11. STING-Activating Polymer-Drug Conjugates for Cancer Immunotherapy.
Sheehy TL; Kwiatkowski AJ; Arora K; Kimmel BR; Schulman JA; Gibson-Corley K; Wilson JT
bioRxiv; 2024 Apr; ():. PubMed ID: 38585879
[TBL] [Abstract][Full Text] [Related]
12. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
13. High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells.
Kang S; Li Y; Bao Y; Li Y
Front Med; 2019 Feb; 13(1):69-82. PubMed ID: 30725257
[TBL] [Abstract][Full Text] [Related]
14. Identification of NY-ESO-1
Zhang H; Sun M; Wang J; Zeng B; Cao X; Han Y; Tan S; Gao GF
Front Immunol; 2021; 12():644520. PubMed ID: 33833762
[TBL] [Abstract][Full Text] [Related]
15. Engineered Nanovaccine Targeting Clec9a
Gou S; Liu W; Wang S; Chen G; Chen Z; Qiu L; Zhou X; Wu Y; Qi Y; Gao Y
Nano Lett; 2021 Dec; 21(23):9939-9950. PubMed ID: 34779631
[TBL] [Abstract][Full Text] [Related]
16. STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer.
Shi J; Liu C; Luo S; Cao T; Lin B; Zhou M; Zhang X; Wang S; Zheng T; Li X
Cell Immunol; 2021 Aug; 366():104384. PubMed ID: 34182334
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Exosomes Functionalized with STING Activation for Personalized Glioblastoma Immunotherapy.
Bao P; Gu HY; Ye JJ; He JL; Zhong Z; Yu AX; Zhang XZ
Adv Sci (Weinh); 2024 Feb; 11(6):e2306336. PubMed ID: 38072677
[TBL] [Abstract][Full Text] [Related]
18. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S
J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363
[TBL] [Abstract][Full Text] [Related]
19. Stimulatory and inhibitory activity of STING ligands on tumor-reactive human gamma/delta T cells.
Serrano R; Lettau M; Zarobkiewicz M; Wesch D; Peters C; Kabelitz D
Oncoimmunology; 2022; 11(1):2030021. PubMed ID: 35127253
[TBL] [Abstract][Full Text] [Related]
20. NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route.
Amissah OB; Chen W; de Dieu Habimana J; Sun Y; Lin L; Liu Y; Wang L; Liu Z; Mukama O; Basnet R; Liu H; Li J; Ding X; Lv L; Chen M; Liang Y; Huang R; Li Z
Cancer Cell Int; 2024 Feb; 24(1):64. PubMed ID: 38336680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
